Table 1.
Dose-response subgroup analysis of the risk of hypertension and type 2 diabetes with parathyroid hormone
| Characteristics | Hypertension | type 2 diabetes | |||||||
|---|---|---|---|---|---|---|---|---|---|
| n | OR (95% CI) | I2 (%) | P * | n | OR (95% CI) | I2 (%) | P * | ||
| Country | |||||||||
| USA | 6 | 1.07(1.04, 1.10) | 65.4 | 0.013 | 4 | 1.03(1.00, 1.06) | 0 | 0.465 | |
| Netherlands | 1 | 1.01(0.99,1.03) | - | - | - | - | - | - | |
| Korean | 1 | 1.01(0.98, 1.04) | - | - | 1 | 0.99(0.97, 1.01) | - | - | |
| Detection method | |||||||||
| electrochemiluminescence immunoassay | 3 | 1.06(1.02, 1.10) | 39.9 | 0.189 | 2 | 1.05(0.99, 1.10) | 44.9 | 0.178 | |
| chemiluminescence assay | 4 | 1.03(1.00, 1.06) | 81.2 | 0.001 | 3 | 1.00(0.98, 1.02) | 0 | 0.558 | |
| immunoradiometric assay | 1 | 1.05(1.02, 1.08) | - | - | - | - | - | - | |
| Sample size | |||||||||
| > 3000 | 4 | 1.04(1.01, 1.06) | 72.3 | 0.013 | 4 | 1.03(1.00, 1.06) | 0 | 0.465 | |
| ≤3000 | 4 | 1.10(1.02, 1.19) | 86.3 | 0 | 1 | 0.99(0.97, 1.01) | - | - | |
| Follow-up | |||||||||
| > 3 | 4 | 1.04(1.01, 1.07) | 74.4 | 0.008 | 1 | 1.08(1.01, 1.15) | - | - | |
| ≤3 | 1 | 1.08(1.04, 1.12) | - | - | 1 | 1.02(0.97, 1.07) | - | - | |
| Sex | |||||||||
| M/W | 7 | 1.05(1.02, 1.07) | 80.2 | 0 | - | - | - | - | |
| M | 1 | 1.22(1.04, 1.42) | - | - | - | - | - | - | |
| Design | |||||||||
| cohort | 5 | 1.05(1.02, 1.08) | 79.1 | 0.001 | 2 | 1.04(1.00, 1.08) | 42.8 | 0.186 | |
| cross-sectional | 3 | 1.07(1.00, 1.15) | 86.8 | 0.001 | 3 | 0.99(0.97, 1.01) | 0 | 0.882 | |
| Hypertension definition | |||||||||
| measured | 7 | 1.05(1.02, 1.07) | 80.2 | 0 | - | - | - | - | |
| self-reported | 1 | 1.22(1.04, 1.42) | - | - | - | - | - | - | |
| Definition | |||||||||
| diabetes | - | - | - | - | 3 | 1.03(1.00, 1.07) | 3.7 | 0.354 | |
| hyperglycaemia | - | - | - | - | 2 | 0.99(0.97, 1.01) | 0 | 0.831 | |
OR: odds ratio; CI: confidence interval; M: men; W: women
*P for heterogeneity within each subgroup estimated by the Cochran Q test